Aurinia pharmaceuticals headquarters. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today issued the following letter to Aurinia shareholders: May 7, 2024 Fellow Shareholders, As a shareholder of Aurinia Pharmaceuticals Inc (Aurinia Pharmaceuticals) is a commercial-stage biopharmaceutical company. Edmonton, Alberta, T5L 4S6, Canada. How much funding has Aurinia Pharmaceuticals raised to date? Aurinia Pharmaceuticals has Industry. Headquarters. Public Company. (now Avalo Therapeutics, Inc. Conference call to be hosted today at 8:30 a. By posting to Jul 1, 2021 · Aurinia Pharmaceuticals Inc. Achieved $50. lupkynis. +1 (888) 500 2905. 2mo. In January of this year, Aurinia Pharmaceuticals announced the U. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the pharmaceutical and Aurinia Pharmaceuticals Inc is a biopharmaceutical company. Primary. 7% amid takeover speculation. Specialties. With a growing pipeline and a dynamic team of proven experts, our work is patient-centric and driven by a sense of urgency. The appointment comes as part of a deal with major stockholder MKT Mike was previously CEO and Director of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new Feb 15, 2024 · On February 15, 2024, Aurinia Pharmaceuticals Inc. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada. Dec 31, 2022 · Aurinia achieved total net revenue of $28. 33%. Type. Total net revenue was $130. | 25,555 followers on LinkedIn. The company collaborates with Otsuka Pharmaceutical and is based in Victoria, Canada. Use the CB Insights Platform to explore Aurinia Pharmaceuticals's full profile. Aurinia Pharmaceuticals voclosporin is used in Find the latest Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. as its new corporate name. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES Founded in 2012, Aurinia Pharmaceuticals a clinical-stage biopharmaceutical company develops and commercializes therapies to treat various diseases in the United States and China. , Inc. Webcast. 250-744-2487. Analysis Showing LUPKYNIS ® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024. 4 million for the nine months ended Please submit sponsorship requests to advocacy@auriniapharma. Share your ideas and get valuable insights from the community of like minded traders and investors Aurinia (NASDAQ: AUPH) is a clinical-stage biopharmaceutical company. It Nov 21, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) soared 6. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or Mar 31, 2024 · <h2>We are passionate about changing the trajectory of autoimmune diseases. 25,080 followers. 5 million for the fourth quarter and full year ended December 31, 2022, respectively. 17. Before Aurinia, Volker served as the Executive Vice President of R&D and Chief Medical Officer at GW Pharmaceuticals; Vice President of Clinical Development for multiple sclerosis, immunology, oncology, and biosimilar products at Teva Pharmaceuticals; and various R&D positions at AstraZeneca and Bayer. This comes after Aurinia's announcement in June Aurinia Pharmaceuticals Inc. AND SUBSIDIARIES. sales and marketing experience, and relevant expertise in rheumatology and lupus markets. Contacts. Dec 20, 2023 · ROCKVILLE, Md. ROCKVILLE, Md. 62. | 25,422 followers on LinkedIn. Food and Drug Administration’s approval of its treatment for adult patients with active lupus nephritis (LN). The Aurinia logo is a modern representation of the lotus flower, a symbol of life and health. Bailey joined Aurinia’s Board of Directors August 18, 2023 Dr. Revenue. Changing the trajectory of autoimmune diseases is something we strive for every day. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Detailed agenda or program description. Aurinia Pharmaceuticals - Products, Competitors, Financials, Employees, Headquarters Locations May 9, 2024 · Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024. May 2, 2024 · Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. , Ltd. 03, revenue of May 2, 2024 · Company reiterates 2024 net product revenue guidance of $200 to $220 million. , prior to its acquisition by Isotechnika in 2013, helping bring the company into a structure capable of advancing voclosporin towards approval. Food and Drug Administration (FDA) has approved LUPKYNIS TM (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult Jan 26, 1999 · Company Description. 3 million for the May 2, 2024 · Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0. | 25,821 followers on LinkedIn. Scientific Presentations & Posters Abstracts Publications Investigator Initated Trials Our Science. (hereinafter Aurinia; headquarters: Victoria, BC, Canada; CEO: Peter Greenleaf), announce that the two companies have entered into a license agreement for Otsuka to acquire exclusive development and marketing rights to Aurinia's lupus nephritis drug candidate May 9, 2024 · About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney and rare diseases. 3 million in total net revenue and $48. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U. Die Aurinia Pharmaceuticals Inc Aktie wird unter der ISIN CA05156V1022 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, London Apr 30, 2024 · Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon Aurinia drops after Q4 miss; strategic review fails Aurinia Pharma GAAP EPS of -$0. Headquarters Location. 4 million and $134. 5 million for the three months ended September 30, 2023 and $55. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. Published: May 02, 2024. $21. "2022 was a year of significant growth BioBuzz is proud to feature the all-female teams at Aurinia Pharmaceuticals and U. (AUPH) stock price, news, historical charts, analyst ratings and financial information from WSJ. In January 2021, the… Aurinia primarily serves sectors related to healthcare providers and institutions involved in the treatment and management of autoimmune conditions. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company’s strategic review. We pursue promising science to address some of the toughest challenges in autoimmune disease. IOVA Iovance Biotherapeutics, Inc. At Aurinia, we embrace the possibility to change the trajectory May 14, 2024 · Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Audio. This was the first time the jet Feb 25, 2020 · Cara Felish comes to Aurinia from Mallinckrodt Pharmaceuticals, where she led the transition of all commercial operations support (Analytics, Sales Operations, Training, Marketing Operations) to a new NJ based headquarters. Aurinia Pharmaceuticals, Inc. Edmonton, Alberta. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the Company’s rare autoimmune and kidney-related disease pipeline. Aurinia Pharmaceuticals Inc headquarters address, phone number and website information and details on other Aurinia Pharmaceuticals Inc's locations and subsidiaries. Billen joined Amgen Aurinia Pharmaceuticals Inc. In September of 2013, the company acquired closely-held Aurinia Pharmaceuticals in an all stock transaction and subsequently adopted Aurinia Pharmaceuticals Inc. May 9, 2024 • 6:00 am EDT. RSS News Feed. Where is Aurinia Pharmaceuticals 's headquarters? Aurinia Pharmaceuticals is located in Victoria, British Columbia, Canada. Its flagship product, LUPKYNIS, treats active lupus nephritis in adult patients. The Company received Aurinia Pharmaceuticals Inc. If you are a healthcare provider and would like to request information on LUPKYNIS ®, contact us at Medinfo@auriniapharma. Aurinia achieved net product revenue of $28. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis . Our resilience to pursue scientific and clinical View the latest Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals Inc peers and key competitor information including headquarters, annual revenue and number of employees. 19 misses by $0. Learn More. Dr. Aug 21, 2023 · Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by www. 2% of the outstanding shares of Aurinia Pharmaceuticals Inc. February 29, 2024 • 8:30 am EST. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. A copy of the press release is attached hereto as Exhibit 99. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are 4 days ago · Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. These View the latest Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) ("Aurinia" or the "Company") today announced that its Board of Directors has appointed two new Aurinia Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for diseases with unmet medical needs. 1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and extending the trend of consistent Our Mission. Interested participants can dial 877-407-9170 Nov 21, 2023 · Aurinia Pharmaceuticals (NASDAQ:AUPH) corporate jet made a trip to Aurinia's headquarters in Edmonton, Canada, according to a Gordon Haskett note on Tuesday. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship. -3. 28. Aurinia Pharma U. It was founded in 2013 and is based in Edmonton, Alberta. Benchmark the company against the market with exclusive information on key competitors Find out more. Karen Smith and Jeffrey A. Mike spearheaded a complex transaction to form the modern-day Aurinia. ). 0 million for the fourth quarter and full year ended December 31, 2022, respectively. Show more. Aurinia Pharmaceuticals Inc Aktie Profil. Aurinia Pharmaceuticals Inc. May 14, 2024 · Aurinia Pharmaceuticals Shareholder Urges Board of Directors to Take Action to Enhance Shareholder Value GENEVA--(BUSINESS WIRE)--Lucien Selce, who owns approximately 2. At Aurinia, we’re laser-focused on helping those who too often are overlooked, excluded, misunderstood, and left to wait. 18 per share a year ago. Entity type. We are a dedicated team of experts, relentless in our pursuit of transformative therapies. 201-500 employees. Pharmacopeia (USP) for Women’s History Month 2021. & EDMONTON, Alberta, November 13, 2023--Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan May 2, 2024 · AUPH. Suite 700. Pleasingly, this was achieved with the help of a 31% boost Dec 31, 2023 · ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Join us. 2013. Who invested in Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has 9 investors including Apple Tree Partners and Lumira Ventures. | 24,801 followers on LinkedIn. The parties entered into a collaborative agreement to build a dedicated manufacturing capacity within Lonza’s Aug 21, 2023 · Aurinia Pharmaceuticals Inc. Nov 2, 2023 · Total net revenue was $54. ACAD ACADIA Pharmaceuticals Inc. Company Profile. 9. Food and Drug Administration Aurinia Pharmaceuticals, Inc. This compares to loss of $0. (hereinafter Otsuka; headquarters: Tokyo; president: Makoto Inoue) and Aurinia Pharmaceuticals Inc. Headquarters See the company profile for Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. Like the lotus, we are resilient in our efforts to develop breakthrough treatments that become the gold standard of patient care, enabling patients to live their fullest lives. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases particularly lupus nephritis. </h2> Business Development bd@auriniapharma. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus Dec 17, 2020 · Otsuka Pharmaceutical Co. 11%. 03 per share versus the Zacks Consensus Estimate of a loss of $0. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or Dr. -4. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus Apr 11, 2023 · Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis Mar 1, 2024 · Aurinia Pharmaceuticals, Inc. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Interactive Chart for Aurinia Pharmaceuticals Inc. | 25,290 followers on LinkedIn. Track Aurinia Pharmaceuticals Inc (AUPH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Understanding the urgency of our mission, we focus our scientific and clinical excellence on developing treatment options that significantly enhance how patients manage their disease. today issued its financial results for the first quarter ended March 31, 2024. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, today announced that the U. Aug 21, 2023 · Aurinia Pharmaceuticals Inc. (AUPH), analyze all the data with a huge range Director, President and CEO. He currently serves as an independent director on the Board of Sutura Therapeutics. The Aurinia stock surge comes amid a report that a Gilead Sciences corporate jet made a trip to Aurinia's headquarters Oct 19, 2023 · Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. Day in and day out, we work hand in Dr. Our strategy is to develop medicines that significantly enhance how patients manage their disease. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U. The information in this Current Report on Form 8-K and the exhibit hereto Aurinia Pharmaceuticals is an equal opportunity employer and considers qualified applicants for employment without regard to race, color, creed, religion, national origin, sex, sexual orientation, gender identity and expression, marital or civil partnership status, pregnancy, age, disability, veteran status or any other protected factor under Apr 16, 2024 · Apr 16, 2024 • 4:00 pm EDT • 4:30 pm EDT. 77 Upper Rock Circle. Investor Relations ir Aurinia Pharmaceuticals Inc. From March 2014 to February 2018, Peter served as CEO and Chairman of Sucampo Nov 21, 2023 · The rumors were sparked by the sighting of a Gilead jet at the Edmonton headquarters of Aurinia, suggesting that discussions might be underway. & EDMONTON, Alberta, May 02, 2024 -- ( BUSINESS Aurinia Pharmaceuticals Inc. (Exact name of registrant as specified in its charter) _____ Alberta, Canada (State or other jurisdiction of incorporation or organization) #140, 14315 - 118 Avenue Edmonton, Alberta T5L 4S6 98-1231763 (Address of principal executive offices) Ronald Flauto is a Director, Medical Affairs Field Lead at Aurinia Pharmaceuticals based in Victoria, British Columbia. Aug 21, 2023 · EDMONTON, Alberta-- (BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. com. #140, 14315 – 118 Avenue. Together, we’re addressing some of the toughest challenges in autoimmune disease and are working everyday to have a positive impact. (AUPH) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives Aug 3, 2023 · AURINIA PHARMACEUTICALS INC. Daniel G. He started with Janssen Pharmaceuticals, first in its Belgian headquarters in cardiovascular global marketing and later launching multiple products in the Canadian market. We are passionate about changing the trajectory of autoimmune diseases. 3 million and $103. --(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Jun 29, 2023 · About Aurinia. Aurinia Pharmaceuticals Corporate Headquarters, Office Locations and Addresses | Craft. & EDMONTON, Alberta---- Aurinia Pharmaceuticals Inc. Founded. Aug 21, 2023 · EDMONTON, Alberta, August 21, 2023 -- ( BUSINESS WIRE )--Aurinia Pharmaceuticals Inc. Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia. Biotechnology, Immunology, Lupus Nephritis, Drug Development, autoimmune, and Nephrology. 1 and is incorporated by reference herein. It provides products for patients suffering from serious diseases with a high unmet medical need. Dec 20, 2023 · About Aurinia. 2M. Rockville, MD 20850. Details regarding the program, sponsorship type, sponsorship objective, therapeutic objectives, and audience. Dec 15, 2020 · VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. A transformational leader and collaborator, Scott has an accomplished history of engaging and inspiring sales forces, creating patient-centric environments Nov 13, 2023 · ROCKVILLE, Md. Bailey joined the board of directors of the Company effective August 18, 2023, bringing with them decades of combined leadership experience in the Jul 21, 2020 · - FDA grants Priority Review and sets PDUFA date of January 22, 2021 - VICTORIA, British Columbia & ROCKVILLE, Md. Aug 21, 2023 · Dr. S. Email Alerts. Interested participants can dial 877-407-9170 Aurinia Pharmaceuticals Inc. 1993. Suggest an edit. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. | 25,536 followers on LinkedIn. ET. 14. (Aurinia) issued a press release announcing its financial results for the quarter and year ended December 31, 2023. US-LUP-2300168 08/23. (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. Company size. While at Mallinckrodt, she also held a dual role as Chief of Staff responsible for several strategic projects and When was Aurinia Pharmaceuticals founded? The company was incorporated in 1993 and its common shares have been listed in Canada since 1996. Community guidelines: 1. Biotechnology Research. See how we are poised to deliver on our mission. com Full Prescribing Information including Boxed WARNING Medication Guide. Show more Mar 8, 2024 · Aurinia Pharmaceuticals managed to reduce its cash burn by 57% over the last twelve months, which suggests it's on the right flight path. At Aurinia, we embrace the possibility to change the trajectory of autoimmune diseases with unmet needs. Total net revenue was $50. EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. , a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. Aurinia Pharmaceuticals is a commercial stage biopharmaceutical company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. co. m. 6. Billen appointed Chair of the Board of Directors. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) June 30, 2023 December 31, 2022 ASSETS Current assets Cash, cash equivalents and restricted cash $ 81,707 $ 94,172 Short-term investments 269,006 Jan 23, 2021 · VICTORIA, British Columbia & ROCKVILLE, Md. Before joining Aurinia, Mike was Director, Global Business Scott Habig joins Aurinia as Chief Commercial Officer with more than 20 years of global and U. BBG000BCRJM5. Billen has over 40 years of experience in the commercialization of pharmaceutical and biotech products both in Europe and North America. Aurinia Pharmaceuticals is headquartered in Victoria, 4464 Markham St #1203, Canada, and has 4 office locations. Locations. Aurinia Pharmaceuticals. Its lupkynis is an orally administered CNI immunosuppressant, to treat adult patients with active lupus nephritis. www. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated autoimmune OUR RESEARCH AND DATA. (Exact name of registrant as specified in its charter) _____ Alberta, Canada (State or other jurisdiction of incorporation or organization) #1203-4464 Markham Street Victoria, British Columbia V8Z 7X8 98-1231763 Jun 14, 2024 • 12:00 pm EDT. May 2, 2024 · Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis Get the latest Aurinia Pharmaceuticals Inc (AUPH) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. <br>Join us. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are Sep 21, 2023 · Thursday, Aurinia tamped down some of the unrest, naming its founder and former CEO Robert Foster to its board of directors. The company pipeline product includes voclosporin, lupkynis, AUR200 and AUR300. AuriniaLN. Biotechnology, Immunology, Lupus Nephritis, ABOUT US. Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Feb 28, 2023 · Aurinia achieved net product revenue of $28. Apr 15, 2024 · Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update. From March 2018 to April 2019, Peter served as the CEO of Cerecor Pharmaceuticals, Inc. FIGI. 8 million for the same period in 2022. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. com at least 3 months in advance of the event and include the following: Letter of request on your letterhead. Public. eo fl ob fs es gd xg ly yl wd